OFATUMUMAB and COVID 19

Overview

COVID 19 is the #9 most commonly reported adverse reaction for OFATUMUMAB, manufactured by Novartis Pharmaceuticals Corporation. There are 1,505 FDA adverse event reports linking OFATUMUMAB to COVID 19. This represents approximately 1.8% of all 82,579 adverse event reports for this drug.

OFATUMUMAB has an overall safety score of 78 out of 100. Patients taking OFATUMUMAB who experience covid 19 should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

COVID 19 is a less commonly reported adverse event for OFATUMUMAB, but still significant enough to appear in the safety profile.

Other Side Effects of OFATUMUMAB

In addition to covid 19, the following adverse reactions have been reported for OFATUMUMAB:

• FATIGUE — 5,388 reports
• HEADACHE — 4,533 reports
• PYREXIA — 3,524 reports
• PAIN — 3,478 reports
• CHILLS — 3,440 reports
• INFLUENZA LIKE ILLNESS — 2,787 reports
• NAUSEA — 1,777 reports
• MULTIPLE SCLEROSIS RELAPSE — 1,614 reports
• ASTHENIA — 1,473 reports
• GAIT DISTURBANCE — 1,398 reports

Other Drugs Associated with COVID 19

The following drugs have also been linked to covid 19 in FDA adverse event reports:

Does OFATUMUMAB cause COVID 19?

COVID 19 has been reported as an adverse event in 1,505 FDA reports for OFATUMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is COVID 19 with OFATUMUMAB?

COVID 19 accounts for approximately 1.8% of all adverse event reports for OFATUMUMAB, making it a notable side effect.

What should I do if I experience COVID 19 while taking OFATUMUMAB?

If you experience covid 19 while taking OFATUMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages